ghk-cu clinical trial human skin wound healing randomized Exploring the Role of Tripeptides in and Regeneration: A Comprehensive Review GHK-Cu for Skin Rejuvenation -

Neuroendocrinology Letters, 24 (3/4), 233-240

doi: 10.1155/2015/679109

GHK-Cu is supplied by Peptide Haus AU exclusively for lawful laboratory and scientific research applications

Most Common Adverse Events Key Observations: Gastrointestinal adverse events are dose-dependent and most pronounced during dose escalation Symptoms typically peak within the first 4-8 weeks and diminish with continued treatment as tolerance develops Slow titration (4-week intervals) significantly reduces the incidence and severity of GI events Most adverse events classified as mild to moderate in severity [9] Discontinuation Rates 7.3% Placebo discontinuation rate [9] 15.8% Cagrilintide 2.4 mg (optimal dose) [9] 24.5% Cagrilintide 4.5 mg (high dose) [9] The majority of discontinuations due to adverse events occurred during the titration phase, with GI symptoms (nausea, vomiting) being the primary reasons